

PERSONAL INFORMATION	
SURNAME	PAPADOPOULOU
NAME	LEFKOTHEA
PLACE OF RESIDENCE	THESSALONIKI, GREECE
e-mail	lefkotea@pharm.auth.gr
CURRENT POSITION(S) : Associate Professor , Lab. of Pharmacology, School of Pharmacy, A.U.Th, Greece	

EDUCATION	
1986-1991	Lab. of Pharmacology, School of Pharmacy, A.U.Th, Greece Ph.D. “Analysis of Anthracyclines-Hemoproteins Interactions in the Hemopoietic System”
1976-1980	DEGREE in Pharmacy, School of Pharmacy, A.U.Th, Greece

TEACHING ACTIVITIES	
UNDERGRADUATE STUDIES	School of Pharmacy, A.U.Th, Greece
• 1999-2020	Toxicology
• 1999-2020	Clinical Pharmacology & Therapeutics
• 2015-2018	Pharmacology II
• 2015-2018	Pharmaceutical Biotechnology
• 2018-2020	Pharmacology I
GRADUATE STUDIES	School of Pharmacy, A.U.Th, Greece
• 2004-2018	Bioinformatics
• 2004-2018	Pharmaceutical Biotechnology II
• 2016-2017	Pharmaceutical Biotechnology I
• 2016-2020	DIRECTOR of «PHARMACOLOGY & THERAPEUTICS»
• 2016-	Innovative therapeutic approaches

MAIN SCIENTIFIC INTERESTS

Molecular mechanisms of action of antineoplastic agents- Cellular Bioenergetics / Production of recombinant proteins – characterization / PTD-mediated protein transduction into mammalian cells, as an alternative therapeutic approach for monogenetic disorders / Mitochondrial Dysfunction in cancer and cardiac failure / IVT-mRNA therapeutics / CAR cell immunotherapy in cancer

PATENT PENDING 9389GR, Patent Submission in National Level, 20190100504 and in International Level, PCT/GR2020000059, AUTH Research Committee - UTH Research Committee
“Method for the development of a delivery platform to produce deliverable PTD-IVT-mRNA therapeutics”

SCIENTIFIC WORK – SELECTED PAPERS

CITATIONS: >1700 (Google Scholar), Index: h: 13, i10: 14

<https://scholar.google.com/citations?user=jYXDyY0AAAAAJ&hl=el&oi=sra>

<https://www.ncbi.nlm.nih.gov/pubmed/?term=Papadopoulou+LC>

<https://orcid.org/0000-0002-5738-969X>

<http://www.pharm.auth.gr/el/faculty/45>

- 1) Miliotou *et al* (2021) Development of a novel PTD-mediated IVT-mRNA Delivery Platform for potential Clinical Application as Protein Therapy approach for Metabolic/Genetic disorders. UNDER REVISION
- 2) Miliotou NA, Papadopoulou LC. (2018) CAR T-cell Therapy: A New Era in Cancer Immunotherapy. **Curr. Pharm. Biotechnol.**, 19(1):5-18.
- 3) Papadopoulou *et al* (2018) Production and Transduction of a Human Recombinant β -Globin Chain into Proerythroid K-562 Cells To Replace Missing Endogenous β -Globin. **Mol. Pharm.** 3;15(12):5665-5677.
- 4) Foltopoulou *et al* (2010) Intracellular delivery of full length recombinant human mitochondrial L-SCO2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient's primary cells. **Biochim. Biophys. Acta**;1802(6):497-508.
- 5) Papadopoulou LC *et al.* (1999) Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. **Nature Genetics** 23(3):333-7.
- 6) Papadopoulou LC *et al* (1999) Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. **Biochem. Pharmacol.** 57(5):481-9.
- 7) Papadopoulou LC and Tsiftoglou AS. (1996) Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). **Biochem. Pharmacol.** 52(5):713-22.
